Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice

Paclitaxel is an effective antitumor agent used for treatment of breast cancer, lung, stomach and pancreas. However, its own adverse effects and the use of toxic Cremophor EL as the solvent limit the application range of this drug. Associated with the albumin-bound nanoparticle paclitaxel (paclitaxe...

Full description

Saved in:
Bibliographic Details
Main Authors: R. N. Alyautdin, B. K. Romanov, В. К. Лепахин, N. D. Bunyatyan, V. A. Merkulov, A. N. Mironov
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2022-06-01
Series:Безопасность и риск фармакотерапии
Subjects:
Online Access:https://www.risksafety.ru/jour/article/view/300
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343365063114752
author R. N. Alyautdin
B. K. Romanov
В. К. Лепахин
N. D. Bunyatyan
V. A. Merkulov
A. N. Mironov
author_facet R. N. Alyautdin
B. K. Romanov
В. К. Лепахин
N. D. Bunyatyan
V. A. Merkulov
A. N. Mironov
author_sort R. N. Alyautdin
collection DOAJ
description Paclitaxel is an effective antitumor agent used for treatment of breast cancer, lung, stomach and pancreas. However, its own adverse effects and the use of toxic Cremophor EL as the solvent limit the application range of this drug. Associated with the albumin-bound nanoparticle paclitaxel (paclitaxel SAN) specifically transported into tumor tissue. This leads to an increase in the antitumor effect, and it reduces the severity of side effects.
format Article
id doaj-art-0790c234e1d34de89f348153b91c9c46
institution Kabale University
issn 2312-7821
2619-1164
language Russian
publishDate 2022-06-01
publisher Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
record_format Article
series Безопасность и риск фармакотерапии
spelling doaj-art-0790c234e1d34de89f348153b91c9c462025-08-20T03:43:01ZrusMinistry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Безопасность и риск фармакотерапии2312-78212619-11642022-06-01021016233Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practiceR. N. Alyautdin0B. K. Romanov1В. К. Лепахин2N. D. Bunyatyan3V. A. Merkulov4A. N. Mironov5Scientific Centre for Expert Evaluation of Medicinal Products Russian FederationScientific Centre for Expert Evaluation of Medicinal Products Russian FederationScientific Centre for Expert Evaluation of Medicinal Products Russian FederationScientific Centre for Expert Evaluation of Medicinal Products Russian FederationScientific Centre for Expert Evaluation of Medicinal Products Russian FederationScientific Centre for Expert Evaluation of Medicinal Products Russian FederationPaclitaxel is an effective antitumor agent used for treatment of breast cancer, lung, stomach and pancreas. However, its own adverse effects and the use of toxic Cremophor EL as the solvent limit the application range of this drug. Associated with the albumin-bound nanoparticle paclitaxel (paclitaxel SAN) specifically transported into tumor tissue. This leads to an increase in the antitumor effect, and it reduces the severity of side effects.https://www.risksafety.ru/jour/article/view/300nanotechnology, albumin nanparticles, paclitaxel
spellingShingle R. N. Alyautdin
B. K. Romanov
В. К. Лепахин
N. D. Bunyatyan
V. A. Merkulov
A. N. Mironov
Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice
Безопасность и риск фармакотерапии
nanotechnology, albumin nanparticles, paclitaxel
title Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice
title_full Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice
title_fullStr Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice
title_full_unstemmed Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice
title_short Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice
title_sort nanoparticle albumin bound paclitaxel first step of nanotechnology into clinical practice
topic nanotechnology, albumin nanparticles, paclitaxel
url https://www.risksafety.ru/jour/article/view/300
work_keys_str_mv AT rnalyautdin nanoparticlealbuminboundpaclitaxelfirststepofnanotechnologyintoclinicalpractice
AT bkromanov nanoparticlealbuminboundpaclitaxelfirststepofnanotechnologyintoclinicalpractice
AT vklepahin nanoparticlealbuminboundpaclitaxelfirststepofnanotechnologyintoclinicalpractice
AT ndbunyatyan nanoparticlealbuminboundpaclitaxelfirststepofnanotechnologyintoclinicalpractice
AT vamerkulov nanoparticlealbuminboundpaclitaxelfirststepofnanotechnologyintoclinicalpractice
AT anmironov nanoparticlealbuminboundpaclitaxelfirststepofnanotechnologyintoclinicalpractice